Morgan Stanley Overweight on Sagent Pharmaceuticals

Morgan Stanley is out with a research report on Sagent Pharmaceuticals SGNT and it has an Overweight rating and a $29 price target on shares. In a note to clients, Morgan Stanley writes, "Total 3Q IMS sales were $44M or +148% Y/Y. This compares with MSe revenue of $43MM suggesting upside to our 3Q estimate after adjusting for limited capture of a key new launch levofloxacin and rebates/chargebacks. That said, IMS read through for Sagent has been variable historically." Shares of SGNT closed at $25.85 yesterday.